Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma

Mitsuyama, Yasuhito; Kageyama, Ken; Shinkawa, Hiroji; Yamamoto, Akira; Jogo, Atsushi; Sohgawa, Etsuji; Tanaka, Shogo; Takemura, Shigekazu; Kubo, Shoji; Ishizawa, Takeaki; Miki, Yukio

doi:10.1016/j.radcr.2023.06.012

Cited by 4 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hemostasis was successfully achieved through selective transarterial embolization, enabling the patient to resume atezolizumab/bevacizumab therapy without experiencing further bleeding. 24 A 75-year-old man experienced dizziness, numbness, and loss of consciousness with severe hypotension during an infusion of atezolizumab/bevacizumab. Diagnosed with anaphylactic shock, the infusion was immediately halted, and 5 mg of dexamethasone was administered.…”

Section: Uncommon But Fatal Iraes Reported In Case Reportsmentioning

confidence: 99%

Complications of immunotherapy in advanced hepatocellular carcinoma

Song,

Yoo,

Kim

et al. 2024

JLC

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) are highly effective in cancer treatment. However, the risks associated with the treatment must be carefully balanced against the therapeutic benefits. Immune-related adverse events (irAEs) are generally unpredictable and may persist over an extended period. In this review, we analyzed common irAEs reported in highly cited original articles and systematic reviews. The prevalent adverse reactions include fatigue, pyrexia, rash, pruritus, diarrhea, decreased appetite, nausea, abdominal pain, constipation, hepatitis, and hypothyroidism. Therefore, it is crucial to conduct evaluations not only of gastrointestinal organs but also of cardiac, neurologic, endocrine (including the frequently affected thyroid), and ophthalmic systems before commencing ICIs. This review further explores commonly reported types of irAEs, specific irAEs associated with each ICI agent, rare yet potentially fatal irAEs, and available treatment options for managing them.

show abstract

Section: Uncommon But Fatal Iraes Reported In Case Reportsmentioning

confidence: 99%